Does 10-day treatment with decitabine + venetoclax improve response in AML and high-risk MDS?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Marina Konopleva, MD Anderson Cancer Center, Houston, US. We asked: Does 10-day treatment with decitabine + venetoclax improve response in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome?

In this video, Marina Konopleva describes the results of an investigator-initiated trial in elderly patients (over the age of 65) with newly diagnosed or relapsed/refractory AML. She describes the low early mortality rates in the two cohort groups, and very high response rates for the newly diagnosed-AML cohort, but notes that a longer follow-up and more patients are required to fully support the findings.